Skip to main content
Erschienen in: Clinical Rheumatology 6/2015

01.06.2015 | Original Article

Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis

verfasst von: Smriti K Raychaudhuri, Ankit Saxena, Siba P Raychaudhuri

Erschienen in: Clinical Rheumatology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Th17 cells are a discrete subset of T cell subpopulation, which produce IL-17 and certain other pro-inflammatory cytokines. A regulatory role of Th17 cells have been proposed in several autoimmune diseases including psoriasis, psoriatic arthritis (PsA), ankylosing spondylitis (AS), rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, and multiple sclerosis. Psoriatic disease is an autoimmune disease which mainly involves skin and joints. Until recently, psoriasis and PsA were thought to be Th1 mediated disease, but after the discovery of IL-17 and IL-17 knockout animal studies as well as human experimental data indicate a crucial role of the Th17 cells in the pathogenesis of psoriasis and PsA. Our research group have not only found abundance of CD4+IL-17+ T cells, mainly the memory phenotype (CD4RO+CD45RACD11a+) in the synovial fluid, but also have shown the existence of a functional IL-17 receptor in synovial fibroblast of psoriatic arthritis patients. Similarly, both animal and human studies indicate a regulatory role of the Th17 cells in AS; most critical observations are that Th17 cytokines (IL-17 and IL-22) can contribute to bone erosion, osteitis and new bone formation the hall mark skeletal features associated with the pathophysiology of AS. In this review article, we have discussed the contributing role of the IL-23/IL-17 axis in the pathogenesis of PsA and AS.
Literatur
1.
Zurück zum Zitat Appel H, Kuhne M, Spiekermann S, Ebhardt H, Grozdanovic Z, Köhler D, Dreimann M, Hempfing A, Rudwaleit M, Stein H, Metz-Stavenhagen P, Sieper J, Loddenkemper C (2006) Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 54(9):2845–51CrossRefPubMed Appel H, Kuhne M, Spiekermann S, Ebhardt H, Grozdanovic Z, Köhler D, Dreimann M, Hempfing A, Rudwaleit M, Stein H, Metz-Stavenhagen P, Sieper J, Loddenkemper C (2006) Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 54(9):2845–51CrossRefPubMed
2.
Zurück zum Zitat Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. Nature 445(7130):866–73CrossRefPubMed Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. Nature 445(7130):866–73CrossRefPubMed
3.
Zurück zum Zitat Raychaudhuri SP (2013) A cutting edge overview: psoriatic disease. Clin Rev Allergy Immunol 44(2):109–13CrossRefPubMed Raychaudhuri SP (2013) A cutting edge overview: psoriatic disease. Clin Rev Allergy Immunol 44(2):109–13CrossRefPubMed
4.
Zurück zum Zitat Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370(9583):263–71CrossRefPubMed Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370(9583):263–71CrossRefPubMed
5.
Zurück zum Zitat Liu Y, Krueger JG, Bowcock AM (2007) Psoriasis: genetic associations and immune system changes. Genes Immun 8(1):1–12CrossRefPubMed Liu Y, Krueger JG, Bowcock AM (2007) Psoriasis: genetic associations and immune system changes. Genes Immun 8(1):1–12CrossRefPubMed
6.
Zurück zum Zitat Gladman DD, Farwell VT, Pellett F, Schentag C, Raham P (2003) HLA is a candidate region for psoriatic arthritis. evidence for excessive HLA sharing in sibling pairs. Hum Immunol 64(9):887–9CrossRefPubMed Gladman DD, Farwell VT, Pellett F, Schentag C, Raham P (2003) HLA is a candidate region for psoriatic arthritis. evidence for excessive HLA sharing in sibling pairs. Hum Immunol 64(9):887–9CrossRefPubMed
7.
Zurück zum Zitat Amherd-Hoekstra A, Naher H, Lorenz HM, Enk AH (2010) Psoriatic arthritis: a review. J Dtsch Dermatol Ges 8(5):332–9CrossRefPubMed Amherd-Hoekstra A, Naher H, Lorenz HM, Enk AH (2010) Psoriatic arthritis: a review. J Dtsch Dermatol Ges 8(5):332–9CrossRefPubMed
8.
Zurück zum Zitat Raychaudhuri SP (2013) Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 44:183–93CrossRefPubMed Raychaudhuri SP (2013) Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 44:183–93CrossRefPubMed
9.
Zurück zum Zitat Raychaudhuri SP, Jiang WY, Raychaudhuri SK (2008) Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol 172(4):961–71CrossRefPubMedCentralPubMed Raychaudhuri SP, Jiang WY, Raychaudhuri SK (2008) Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol 172(4):961–71CrossRefPubMedCentralPubMed
10.
Zurück zum Zitat Raychaudhuri SP, Kundu-Raychaudhuri S, Tamura K, Masunaga T, Kubo K, Hanaoka K et al (2008) FR255734, a humanized, Fc-Silent, anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model. J Invest Dermatol 128(8):1969–76. doi:10.1038/jid.2008.38 CrossRefPubMed Raychaudhuri SP, Kundu-Raychaudhuri S, Tamura K, Masunaga T, Kubo K, Hanaoka K et al (2008) FR255734, a humanized, Fc-Silent, anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model. J Invest Dermatol 128(8):1969–76. doi:10.​1038/​jid.​2008.​38 CrossRefPubMed
11.
Zurück zum Zitat Raychaudhuri SP, Mitra A, Datta Mitra A, Abria C, Raychaudhuri SK (2014) Th9 cells in inflammatory cascades of autoimmune arthritis. Arthritis Rheum 66(11):S708, Abstract 1602 Raychaudhuri SP, Mitra A, Datta Mitra A, Abria C, Raychaudhuri SK (2014) Th9 cells in inflammatory cascades of autoimmune arthritis. Arthritis Rheum 66(11):S708, Abstract 1602
12.
Zurück zum Zitat Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG (2013) The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 34(4):174–81CrossRefPubMedCentralPubMed Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG (2013) The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 34(4):174–81CrossRefPubMedCentralPubMed
13.
Zurück zum Zitat Kruithof E, Baeten D, Van den Bosch F, Mielants H, Veys EM, De Keyser F (2005) Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis 64:529–36CrossRefPubMedCentralPubMed Kruithof E, Baeten D, Van den Bosch F, Mielants H, Veys EM, De Keyser F (2005) Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis 64:529–36CrossRefPubMedCentralPubMed
14.
Zurück zum Zitat Raychaudhuri SP, Raychaudhuri SK (2004) Role of NGF and neurogenic inflammation in the pathogenesis of psoriasis. Prog Brain Res 146:433–7PubMed Raychaudhuri SP, Raychaudhuri SK (2004) Role of NGF and neurogenic inflammation in the pathogenesis of psoriasis. Prog Brain Res 146:433–7PubMed
15.
Zurück zum Zitat Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T et al (2010) Molecular dissection of psoriasis: integrating genetics and biology. J Invest Dermatol 130(5):1213–26CrossRefPubMed Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T et al (2010) Molecular dissection of psoriasis: integrating genetics and biology. J Invest Dermatol 130(5):1213–26CrossRefPubMed
16.
Zurück zum Zitat Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34(3):J314–21CrossRefPubMed Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34(3):J314–21CrossRefPubMed
17.
Zurück zum Zitat Bowes J, Orozco G, Flynn E, Ho P, Brier R, Marzo-Ortega H et al (2011) Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Ann Rheum Dis 70:1641–4CrossRefPubMedCentralPubMed Bowes J, Orozco G, Flynn E, Ho P, Brier R, Marzo-Ortega H et al (2011) Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Ann Rheum Dis 70:1641–4CrossRefPubMedCentralPubMed
18.
Zurück zum Zitat Filer C, Ho P, Smith RL, Griffiths C, Young HS, Worthington J et al (2012) Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum 64(4):1302CrossRef Filer C, Ho P, Smith RL, Griffiths C, Young HS, Worthington J et al (2012) Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum 64(4):1302CrossRef
19.
Zurück zum Zitat Huffmeier U, Uebe S, Ekici AB, Bowes J, Giardina E, Korendowych E et al (2010) Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 42:996–9CrossRefPubMedCentralPubMed Huffmeier U, Uebe S, Ekici AB, Bowes J, Giardina E, Korendowych E et al (2010) Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 42:996–9CrossRefPubMedCentralPubMed
20.
Zurück zum Zitat WTCCC & TASC (2007) Association scan of 14,500 nonsynonymous SNPs in four diseases identifiesautoimmunity variants. Nat Genet 39:1329–1337CrossRefPubMedCentral WTCCC & TASC (2007) Association scan of 14,500 nonsynonymous SNPs in four diseases identifiesautoimmunity variants. Nat Genet 39:1329–1337CrossRefPubMedCentral
22.
Zurück zum Zitat Lories RJ, McInnes IB (2012) Primed for inflammation: enthesis-resident T cells. Nat Med 18(7):1018–9CrossRefPubMed Lories RJ, McInnes IB (2012) Primed for inflammation: enthesis-resident T cells. Nat Med 18(7):1018–9CrossRefPubMed
23.
Zurück zum Zitat Baeten D, Braun J, Baraliakos X et al (2014) Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a 52-week phase 3 randomized placebo-controlled trial with intravenous loading and subcutaneous maintenance dosing. Arthritis Rheum 66:S360, Abstract 819 Baeten D, Braun J, Baraliakos X et al (2014) Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a 52-week phase 3 randomized placebo-controlled trial with intravenous loading and subcutaneous maintenance dosing. Arthritis Rheum 66:S360, Abstract 819
24.
Zurück zum Zitat Sieper J, Braun J, Baraliakos X et al (2014) Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a phase 3, randomized, placebo-controlled trial with subcutaneous loading and maintenance dosing. Arthritis Rheum 66:S232, Abstract 536 CrossRef Sieper J, Braun J, Baraliakos X et al (2014) Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a phase 3, randomized, placebo-controlled trial with subcutaneous loading and maintenance dosing. Arthritis Rheum 66:S232, Abstract 536 CrossRef
25.
Zurück zum Zitat Mease PJ, Genovese MC, Greenwalk MW, Ritchlin CT, Beaulier AD, Deodhar A et al (2014) Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 370(24):2295–306CrossRefPubMed Mease PJ, Genovese MC, Greenwalk MW, Ritchlin CT, Beaulier AD, Deodhar A et al (2014) Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 370(24):2295–306CrossRefPubMed
26.
Zurück zum Zitat Papp KA, Leonardi C, Menter A, Ortonne JP, Kreuger JG, Kricorian G et al (2012) Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 366(13):1181–9CrossRefPubMed Papp KA, Leonardi C, Menter A, Ortonne JP, Kreuger JG, Kricorian G et al (2012) Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 366(13):1181–9CrossRefPubMed
27.
Zurück zum Zitat Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK et al (1995) Human IL-17: a novel cytokine derived from T cells. J Immunol 155(12):5483–6PubMed Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK et al (1995) Human IL-17: a novel cytokine derived from T cells. J Immunol 155(12):5483–6PubMed
29.
Zurück zum Zitat Kuestner RE, Taft DW, Haran A, Brandt CS, Brender T, Lum K et al (2007) Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17 F. J Immunol 179(8):5462–73CrossRefPubMedCentralPubMed Kuestner RE, Taft DW, Haran A, Brandt CS, Brender T, Lum K et al (2007) Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17 F. J Immunol 179(8):5462–73CrossRefPubMedCentralPubMed
30.
Zurück zum Zitat Liang SC, Long AJ, Bennett F, Whitters MJ, Karim R, Collins M et al (2007) An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J Immunol 179(11):7791–9CrossRefPubMed Liang SC, Long AJ, Bennett F, Whitters MJ, Karim R, Collins M et al (2007) An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J Immunol 179(11):7791–9CrossRefPubMed
31.
Zurück zum Zitat Hymowitz SG, Filvaroff EH, Jp Y, Lee J, Cai L, Risser P et al (2001) IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J 20(19):5332–41CrossRefPubMedCentralPubMed Hymowitz SG, Filvaroff EH, Jp Y, Lee J, Cai L, Risser P et al (2001) IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J 20(19):5332–41CrossRefPubMedCentralPubMed
32.
Zurück zum Zitat Yao Z, Spriggs MK, Derry JM, Strockbine L, Park LS, Vanden Bos T et al (1997) Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 9(11):794–800CrossRefPubMed Yao Z, Spriggs MK, Derry JM, Strockbine L, Park LS, Vanden Bos T et al (1997) Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 9(11):794–800CrossRefPubMed
34.
Zurück zum Zitat Toy D, Kugler D, Wolfson M, Vanden Bos T, Gurgel J, Derry J et al (2006) Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 177(1):36–9CrossRefPubMed Toy D, Kugler D, Wolfson M, Vanden Bos T, Gurgel J, Derry J et al (2006) Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 177(1):36–9CrossRefPubMed
35.
Zurück zum Zitat Coimbra S, Figueriredo A, Castro E, Rocha-Pereira P, Santos-Silva A (2012) The roles of cells and cytokines in the pathogenesis of psoriasis. Int J Dermatol 51(4):389–95, quiz 395-8 CrossRefPubMed Coimbra S, Figueriredo A, Castro E, Rocha-Pereira P, Santos-Silva A (2012) The roles of cells and cytokines in the pathogenesis of psoriasis. Int J Dermatol 51(4):389–95, quiz 395-8 CrossRefPubMed
36.
Zurück zum Zitat Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F et al (2004) Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199(1):125–30CrossRefPubMedCentralPubMed Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F et al (2004) Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199(1):125–30CrossRefPubMedCentralPubMed
37.
Zurück zum Zitat Piskin G, Sylva-Steenland R, Bos JD, Teunissen MB (2006) In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 176(3):1908–15CrossRefPubMed Piskin G, Sylva-Steenland R, Bos JD, Teunissen MB (2006) In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 176(3):1908–15CrossRefPubMed
38.
Zurück zum Zitat Bovenschen HJ, van de Kerkhof PC, van Erp PE, Woestenenk R, Joosten I, Koenen HJ (2011) Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol 131(9):1853–60CrossRefPubMed Bovenschen HJ, van de Kerkhof PC, van Erp PE, Woestenenk R, Joosten I, Koenen HJ (2011) Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol 131(9):1853–60CrossRefPubMed
39.
Zurück zum Zitat Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein W, Mattson JD et al (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8(9):950–7CrossRefPubMed Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein W, Mattson JD et al (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8(9):950–7CrossRefPubMed
40.
Zurück zum Zitat Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS et al (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 128(5):1207–11CrossRefPubMed Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS et al (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 128(5):1207–11CrossRefPubMed
41.
Zurück zum Zitat Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K (2009) Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol 160(2):319–24CrossRefPubMed Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K (2009) Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol 160(2):319–24CrossRefPubMed
42.
Zurück zum Zitat van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD et al (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 182(9):5836–45CrossRefPubMed van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD et al (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 182(9):5836–45CrossRefPubMed
43.
Zurück zum Zitat Homey B, Dieu-Nosjean MC, Wiesenborn A, Massacrier C, Pin JJ, Oldham E et al (2000) Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 164(12):6621–32CrossRefPubMed Homey B, Dieu-Nosjean MC, Wiesenborn A, Massacrier C, Pin JJ, Oldham E et al (2000) Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 164(12):6621–32CrossRefPubMed
44.
Zurück zum Zitat Girolomoni G, Mrowietz U, Paul C (2012) Psoriasis: rationale for targeting interleukin-17. Br J Dermatol 167(4):717–24CrossRefPubMed Girolomoni G, Mrowietz U, Paul C (2012) Psoriasis: rationale for targeting interleukin-17. Br J Dermatol 167(4):717–24CrossRefPubMed
45.
Zurück zum Zitat Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan K, Suarex-Farinas M, Cardinale I et al (2008) Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159(5):1092–102PubMedCentralPubMed Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan K, Suarex-Farinas M, Cardinale I et al (2008) Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159(5):1092–102PubMedCentralPubMed
46.
Zurück zum Zitat Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M et al (2006) Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203(10):2271–9CrossRefPubMedCentralPubMed Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M et al (2006) Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203(10):2271–9CrossRefPubMedCentralPubMed
47.
Zurück zum Zitat Gutowska-Owsiak D, Schaupp AL, Salimi M, Selvakumar TA, McPherson T, Taylor S et al (2012) IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol 21(2):104–10CrossRefPubMed Gutowska-Owsiak D, Schaupp AL, Salimi M, Selvakumar TA, McPherson T, Taylor S et al (2012) IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol 21(2):104–10CrossRefPubMed
48.
Zurück zum Zitat Raychaudhuri SP, Raychaudhuri SK, Genovese MC (2012) IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 359(1-2):419–29CrossRefPubMed Raychaudhuri SP, Raychaudhuri SK, Genovese MC (2012) IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 359(1-2):419–29CrossRefPubMed
49.
Zurück zum Zitat Chabaud M, Lubberts E, Joosten L, van den Berg W, Miossec P (2001) IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 3:168–177CrossRefPubMedCentralPubMed Chabaud M, Lubberts E, Joosten L, van den Berg W, Miossec P (2001) IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 3:168–177CrossRefPubMedCentralPubMed
50.
Zurück zum Zitat Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan AD (2002) IL-17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 61(8):704–713CrossRefPubMedCentralPubMed Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan AD (2002) IL-17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 61(8):704–713CrossRefPubMedCentralPubMed
51.
Zurück zum Zitat Nakae S, Nambu A, Sudo K, Iwakura Y (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171(11):6173–6177CrossRefPubMed Nakae S, Nambu A, Sudo K, Iwakura Y (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171(11):6173–6177CrossRefPubMed
52.
Zurück zum Zitat Koenders MI, Kolls JK, Oppers-Walgreen B, van den Bersselaar L, Joosten LA, Schurr JR et al (2005) Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated Streptococcal cell wall induced arthritis. Arthritis Rheum 52(10):3239–3247CrossRefPubMed Koenders MI, Kolls JK, Oppers-Walgreen B, van den Bersselaar L, Joosten LA, Schurr JR et al (2005) Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated Streptococcal cell wall induced arthritis. Arthritis Rheum 52(10):3239–3247CrossRefPubMed
53.
Zurück zum Zitat Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova FE et al (2005) Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 167(1):141–149CrossRefPubMedCentralPubMed Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova FE et al (2005) Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 167(1):141–149CrossRefPubMedCentralPubMed
54.
Zurück zum Zitat Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S et al (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103(9):1345–1352CrossRefPubMedCentralPubMed Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S et al (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103(9):1345–1352CrossRefPubMedCentralPubMed
55.
Zurück zum Zitat Australo-Anglo-American Spondyloarthritis Consortium (TASC), Reveille JD, Sims AM, Danoy P, Evans DM, Leo P, Pointon JJ et al (2010) Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 42(2):123–127CrossRef Australo-Anglo-American Spondyloarthritis Consortium (TASC), Reveille JD, Sims AM, Danoy P, Evans DM, Leo P, Pointon JJ et al (2010) Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 42(2):123–127CrossRef
56.
Zurück zum Zitat Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z, Liao F, Xia G, Wang S, Xu S, Xu J, Zhang L, Ye D (2011) Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol 30:269–273CrossRefPubMed Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z, Liao F, Xia G, Wang S, Xu S, Xu J, Zhang L, Ye D (2011) Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol 30:269–273CrossRefPubMed
57.
Zurück zum Zitat Zeng L, Lindstrom MJ, Smith JA (2011) Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide. Arthritis Rheum 63(12):3807–17CrossRefPubMedCentralPubMed Zeng L, Lindstrom MJ, Smith JA (2011) Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide. Arthritis Rheum 63(12):3807–17CrossRefPubMedCentralPubMed
58.
Zurück zum Zitat Appel H, Maier R, Wu P, Scheer R, Hempfing A, Kayser R, Thiel A, Radbruch A, Loddenkemper C, Sieper J (2011) Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 13:R95CrossRefPubMedCentralPubMed Appel H, Maier R, Wu P, Scheer R, Hempfing A, Kayser R, Thiel A, Radbruch A, Loddenkemper C, Sieper J (2011) Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 13:R95CrossRefPubMedCentralPubMed
59.
Zurück zum Zitat Singh AK, Misra R, Aggarwal A (2011) Th17 associated cytokines in patients with reactive arthritis/undifferentiated spondylarthropathy. Clin Rheumatol 30:771–776CrossRefPubMed Singh AK, Misra R, Aggarwal A (2011) Th17 associated cytokines in patients with reactive arthritis/undifferentiated spondylarthropathy. Clin Rheumatol 30:771–776CrossRefPubMed
60.
Zurück zum Zitat Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM (2003) Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111(6):821–31CrossRefPubMedCentralPubMed Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM (2003) Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111(6):821–31CrossRefPubMedCentralPubMed
61.
Zurück zum Zitat Sherlock JP, Joyce-Shaikh B, Turner SP et al (2012) IL-23 induces spondyloarthropathy by acting on ROR-gammatþ CD3þCD4-CD8- entheseal resident T cells. Nat Med 18:1069–1076CrossRefPubMed Sherlock JP, Joyce-Shaikh B, Turner SP et al (2012) IL-23 induces spondyloarthropathy by acting on ROR-gammatþ CD3þCD4-CD8- entheseal resident T cells. Nat Med 18:1069–1076CrossRefPubMed
Metadaten
Titel
Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis
verfasst von
Smriti K Raychaudhuri
Ankit Saxena
Siba P Raychaudhuri
Publikationsdatum
01.06.2015
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 6/2015
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-015-2961-7

Weitere Artikel der Ausgabe 6/2015

Clinical Rheumatology 6/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.